Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q1 2017 call → NOWe need to determine if the transcript describes a current waiting period where the company is paying costs now for something not yet earning, with a specific near-dated event that is already visible and being worked toward. Let's scan the transcript for such a situation. The management discusses various investments, acquisitions, and product launches. Key points: - They mention "incremental growth investments" and "reinvest in our businesses" but that's general. - They discuss Cepheid performing well, not a waiting period. - They discuss new product launches like Biomek i-Series, but that's already launched. - They discuss the acquisition of AVT, but that's just closed. - They discuss the transfer of Pall water business to water platform, but that's just a transfer. Is there any specific mention of a cost being borne now for a future benefit with a specific near-term event? For example, they mention "we are initiating second quarter adjusted diluted net EPS guidance" and "we continue to expect full-year 2017 adjusted diluted net earnings per share to be in the range of $3.85 to $3.95." That's not a waiting period. They mention "we will continue to focus primarily on small and midsized acquisitions." Not a waiting period. They mention "we are reinvesting in our businesses" but that's normal. They mention "we are in the process of integrating Cepheid" but that's already performing well. They mention "we are investing in R&D" but that's normal. Is there any specific cost like a facility being built, a new product launch that hasn't yet generated revenue? They mention "we are looking at probably the first, early part of next year, maybe even as early as first quarter next year for that launch" regarding the Cepheid omni platform. That is a specific future event. But are they currently paying costs for it? They say "we've got a chance to work directly with the R&D teams and the product management teams that are on omni right now." That suggests they are investing in R&D for that platform. But is that a defined waiting period? They are paying for R&D now, and the launch is early next year. That could be a waiting period. However, is it described as a cost that is currently landing in results? They don't explicitly say that the R&D for omni is causing a drag on earnings. They mention "incremental growth investments" but not specifically for omni.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.